(English Captions) TOCILIZUMAB AND REMDESIVIR UNSAFE AND INEFFECTIVE TREATMENTS AND PROTOCOLS
INTERNATIONAL CONFERENCE IN PORTUGAL
Natalia Prego Medical Doctor
Remdesivir and tocilizumab are drugs that have been the main components of the therapeutic protocols established in most hospitals in the world, applied to patients with covid syndrome.
Since March 2020 they have been established without any type of study and clinical trial that has guaranteed, with scientific rigor, their safety and efficacy in patients with covid syndrome.
Mortality in the ICU of patients treated with these drugs has been too high to continue two and a half years later with the same protocols.
Protocols with extremely expensive, ineffective and unsafe drugs, without minimally considering the use of other drugs that are safer, more effective and much cheaper.
Far from developing an attitude of improving the quality of care for patients and rectifying erroneous and mistaken treatments, health institutions unjustifiably block, censor and criticize other types of treatment, with biased information and without professional and scientific rigor
REFERENCES :
https://cima.aemps.es/cima/dochtml/ft/1201459001/FT_1201459001.html
https://cima.aemps.es/cima/dochtml/ft/08492003/FT_08492003.html
❤️ We need help to continue fighting for the defense of the Right to life and the rest of Human Rights. Need to give continuity to research work, scientific studies and develop all necessary actions in order to publicly defend bioethics in medicine, fundamental rights and public freedoms. Freedom of expression, freedom of treatment and method, informed consent, aid to those affected by adverse effects of vaccines.
We need you to support us, we are defending human dignity and life above all else.
❤️ Be a supporter, your support and support is very important.
❤️ ** 🄸🄱🄰🄽 Beneficiary: NATALIA PREGO CANCELED
CONCEPT: DONATION Iban Code ES68 2100 1785 4102 0024 5298
❤️ 👇Santander Bank
IBAN ES3900758929650700394090 (from outside the European community BICMM-SWIFT CODE
